ArticleClinical ophthalmology (Auckland, N.Z.)2026
Effects of Lotilaner Ophthalmic Solution, 0.25% on
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25% compared with vehicle in Patients and Methods: This was a pooled analysis of two prospective, randomized, double-masked studies of Results: On Days 43 and 85, there was a statistically significantly higher proportion of patients in the lotilaner group versus the vehicle group with collarette reduction to grade 0 (0-2 collarettes/lid) (44.7% vs 0.0% and 65.8% vs 0.0%) and grade 0 or 1 (0-10 collarettes/lid) (81.6% vs 8.8% and 100% vs 0.0%) (all p<0.001). Mean MGSS, MGYLS, and MGYCLS in the lotilaner group were statistically significantly higher than in the vehicle group. The proportion of lotilaner patients achieving improvement to ≥ 3 glands with clear meibum (grade 3) was significantly higher than the vehicle group on Day 43 (44.7% vs 17.6%, p<0.05) and Day 85 (78.9% vs 18.2%, p<0.001). At Days 43 and 85, fluctuating vision, itching, burning, and redness were significantly better in the lotilaner group than in the vehicle group. No serious treatment-related AEs were reported. Conclusion: In patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.